Kirin

Kyowa Kirin welcomes the decision that NICE will revisit their appraisal of the innovative systemic treatment, POTELIGEO®▼ (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma

Friday, June 11, 2021 - 1:51pm

Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.

Key Points: 
  • Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.
  • We strongly believe in the clinical and cost effectiveness of POTELIGEO and will continue a dialogue with NICE and NHS England.
  • We are hopeful that NICEs reassessment might bring parity with the SMCs decision to make mogamulizumab available in Scotland.
  • You can learn more about the business of Kyowa Kirin at:

Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones

Tuesday, May 4, 2021 - 8:30pm

Prior to that, she held multiple leadership roles in Medical Affairs, including safety risk management and field medical affairs for Novartis.

Key Points: 
  • Prior to that, she held multiple leadership roles in Medical Affairs, including safety risk management and field medical affairs for Novartis.
  • Under her leadership the company will grow and improve capabilities for Global Medical Information, Medical IT and Digital, Medical Communications and Publications, and Training.
  • Deb has built a very strong North American Medical Affairs organization and I\'m thrilled to partner with her, and the entire Global Medical Affairs community, to take our team even further as One Kyowa Kirin.
  • You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.\n'

Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

Wednesday, March 31, 2021 - 9:30pm

BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.

Key Points: 
  • BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.
  • Kyowa Kirin Canada, Inc. and BioWa, Inc., both maintain their current structure as subsidiaries of Kyowa Kirin, Inc. and Kyowa Kirin USA Holdings, Inc. respectively.
  • The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these opportunities," says Gary Zieziula, President, Kyowa Kirin North America.
  • You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

Monday, March 29, 2021 - 12:00pm

We are pleased to expand our agreement for this promising first-in-class asset with Kyowa Kirin, a global leader in innovative antibody engineering technology, said Mike Cola, Chief Executive Officer of Cerecor.

Key Points: 
  • We are pleased to expand our agreement for this promising first-in-class asset with Kyowa Kirin, a global leader in innovative antibody engineering technology, said Mike Cola, Chief Executive Officer of Cerecor.
  • Under the terms of the agreement, Cerecor will receive exclusive rights for the development, manufacturing and commercialization of the antibody for all indications worldwide including the United States, Europe and Japan.
  • Kyowa Kirin has an option to retain the rights in Japan.
  • CERC-002 is a fully human anti-LIGHT or tumor necrosis factor superfamily member 14 (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd.

Harvard University and Kyowa Kirin Enter Strategic Research Alliance

Thursday, February 25, 2021 - 7:00pm

Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) announce that they have entered into a strategic research alliance.

Key Points: 
  • Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) announce that they have entered into a strategic research alliance.
  • Projects selected for funding and scientific collaboration will be identified by a Joint Steering Committee, comprising membership from both Harvard and Kyowa Kirin.
  • Harvard OTDs long-running alliance program creates multi-year, collaborative relationships between the University and corporate partners.
  • In establishing discussions with Kyowa Kirin that led to the creation of this research alliance, OTD was assisted by Gemseki, Inc. , a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), a preclinical CRO in Japan.

A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan

Monday, February 8, 2021 - 1:00am

TOKYO, Feb. 7, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Key Points: 
  • TOKYO, Feb. 7, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).
  • Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.
  • G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014.
  • This investigational product has a function to deliver G-Lasta into the patient's body after a specified time.

A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan

Monday, February 8, 2021 - 1:00am

TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Key Points: 
  • TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).
  • Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.
  • G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014.
  • This investigational product has a function to deliver G-Lasta into the patient's body after a specified time.

InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

Wednesday, December 9, 2020 - 1:10pm

InveniAI and Kyowa Kirin have been collaborating since 2018, to maximize Kyowa Kirins portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications utilizing AlphaMeld.

Key Points: 
  • InveniAI and Kyowa Kirin have been collaborating since 2018, to maximize Kyowa Kirins portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications utilizing AlphaMeld.
  • Through this expansion, Kyowa Kirin will leverage AlphaMeld for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies that address the enduring unmet needs of patients across multiple diseases.
  • Under the terms of the agreement, Kyowa Kirin will select multiple programs to advance into clinical development.
  • Under the terms of the collaboration, InveniAI will receive an upfront payment, development and commercial milestones, and royalties.

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

Tuesday, December 1, 2020 - 7:30am

Under the terms of the licensing and distribution agreement, Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR in China.

Key Points: 
  • Under the terms of the licensing and distribution agreement, Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR in China.
  • It is a rare disease with about 30,000 diagnosed patients in the world and accounts for approximately 45% of primary cutaneous lymphomas1.
  • Dr. Tan Boon Heon, Kyowa Kirins President in the Asia Pacific, commented: Kyowa Kirin is committed to delivering life-changing value to people living with severe diseases.
  • VALCHLOR joins a growing portfolio of innovative products that we are introducing in the rare disease, nephrology and hemato-oncology space in Asia.

Kyowa Hakko Bio Establishes New Facility in Thailand to Supply Human Milk Oligosaccharides Worldwide

Wednesday, November 4, 2020 - 3:00pm

TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.

Key Points: 
  • TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.
  • Kyowa Hakko Bio decided on the move with expectations of a future increase in global demand for HMOs.
  • The new facility is to be established at Kyowa Hakko Bio's subsidiary Thai Kyowa Biotechnologies Co., Ltd. (Thai Kyowa) in Rayong Province, Thailand.
  • Kyowa Hakko Bio will be able to secure a competitive advantage through its strain development and manufacturing process development capabilities.